<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00832884</url>
  </required_header>
  <id_info>
    <org_study_id>00570-FB</org_study_id>
    <nct_id>NCT00832884</nct_id>
    <nct_alias>NCT00720863</nct_alias>
  </id_info>
  <brief_title>The Safety of Intravenous Lacosamide</brief_title>
  <official_title>IV Lacosamide: The Safety of Intravenous Lacosamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Le Bonheur Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Le Bonheur Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of IV Lacosamide in children with partial-onset epilepsy, ages 4-35&#xD;
      years old, inclusive, who are either unable to take oral medication or require intravenous&#xD;
      administration of IV Lacosamide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lacosamide tablets and intravenous formulations were both approved in the United States in&#xD;
      the fall of 2008. Lacosamide is indicated for use as adjunctive therapy in the treatment of&#xD;
      partial onset seizure disorder in patients' age seventeen years and older. A parenteral&#xD;
      dosage form of Lacosamide is desirable for patients who are temporarily unable to take&#xD;
      medication orally. The objective of this study is to evaluate the safety of IV Lacosamide in&#xD;
      children with epilepsy, ages 4 to 35 years, who are either unable to take oral medication, or&#xD;
      whom parenteral administration of IV Lacosamide is desirable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of IV Lacosamide given as a rapid infusion.</measure>
    <time_frame>one year</time_frame>
    <description>The safety of IV Lacosamide will be assessed in patients in whom parental administration of Lacosamide is warranted.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 50 mg, once, 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 100 mg, once, 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 150 mg, once, 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 200 mg, once, 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 50 mg, once, 15 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 100 mg, once, 15 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 150 mg, once, 15 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lacosamide, IV, 200 mg, once, 15 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.&#xD;
0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_label>Group 3A</arm_group_label>
    <arm_group_label>Group 3B</arm_group_label>
    <arm_group_label>Group 4A</arm_group_label>
    <arm_group_label>Group 4B</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a diagnosis of epilepsy and have received anti-epileptic drug&#xD;
             therapy prior to initiation of IV Lacosamide&#xD;
&#xD;
          -  Patients must have a medical condition in which the parenteral administration of&#xD;
             Lacosamide is desirable.&#xD;
&#xD;
          -  Patients may be male or female.&#xD;
&#xD;
          -  Patients must be 4 years of age or older, and less than age 35 years.&#xD;
&#xD;
          -  Patient or his / her legally authorized representative must sign an informed consent&#xD;
             form prior to any study specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from entry into the study if any of the following are true:&#xD;
&#xD;
          -  Patient has previously participated in any other intravenous Lacosamide study.&#xD;
&#xD;
          -  Patient has status epilepticus within the last 3 months.&#xD;
&#xD;
          -  Patient has a history of drug allergy to Lacosamide.&#xD;
&#xD;
          -  Patient is pregnant.&#xD;
&#xD;
          -  Patient has taken experimental drug within last 30 days.&#xD;
&#xD;
          -  Patient with significant hepatic or renal disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Wheless, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LeBonheur Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LeBonheur Children's Medical Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lebonheur.org</url>
    <description>Study site website</description>
  </link>
  <results_reference>
    <citation>Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia. 2008 Mar;49(3):418-24. Epub 2007 Sep 19.</citation>
    <PMID>17888078</PMID>
  </results_reference>
  <results_reference>
    <citation>Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001 Jan;43(1):11-58.</citation>
    <PMID>11137386</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2009</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Le Bonheur Children's Hospital</investigator_affiliation>
    <investigator_full_name>James W. Wheless</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>partial</keyword>
  <keyword>onset</keyword>
  <keyword>epilepsy</keyword>
  <keyword>pediatric</keyword>
  <keyword>lacosamide</keyword>
  <keyword>partial onset epilepsy</keyword>
  <keyword>vimpat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

